Biohaven shares rose about 26% after the agency accepted a resubmission for troriluzole and planned an advisory panel. The rejection last November turned on the use of external controls, and the new filing adds analyses rather than a new randomized trial.
The Food and Drug Administration has accepted for review Biohaven's resubmitted application for Vyglxia, or troriluzole, in spinocerebellar ataxia, the company said in a regulatory filing on Thursday.
According to the filing, the FDA considers the resubmission "a complete response to the November 4, 2025 action letter" and has set a user-fee goal date in the first quarter of 2027. The agency also plans to convene its Peripheral and Central Nervous System Advisory Committee, with a meeting date "forthcoming in the near term."
Biohaven shares traded at about $14.85 at 1:43 p.m. Eastern, up 26% from Wednesday's $11.75 close. The stock first jumped in premarket trading within minutes of the 7 a.m. disclosure and touched $16.54 after the open before easing. The SPDR S&P Biotech ETF was down 1.2%, so the move was specific to the company. At the afternoon price, Biohaven was worth about $2.24 billion, roughly $470 million more than a day earlier.
What acceptance does, and does not, change
Acceptance changes the regulatory path: Biohaven has a live application and a deadline where last year it had a rejection.
It does not change the nature of the evidence. The November 2025 complete response letter cited "issues that can be inherent to real-world evidence and external control studies including potential bias," according to the company's account at the time. Before the trial, by the company's account, the FDA had warned that "a large and robust treatment effect would be needed to overcome the biases of an externally controlled trial." The Phase 3 study missed its primary endpoint on the f-SARA scale.
The resubmission, by Biohaven's description, "included new positive supportive analyses." It did not include a new randomized trial. The filing itself cautions that the goal date "does not assure that the FDA will act by that date or approve" the drug, and that the agency could extend the review or issue another rejection.
The case for and against
The bullish case rests on unmet need and an open forum. There is no FDA-approved therapy for spinocerebellar ataxia, analysts at William Blair noted, and an advisory panel gives outside experts a chance to weigh that against the agency's objections. William Blair said it continues to see troriluzole's risk/benefit as favorable, citing natural-history comparisons that show a 50% to 70% slower rate of decline at the 200-milligram dose. "The Vyglxia AdCom will be the most de-risking event here," the firm wrote.
The bearish case is that the market has already priced a lot of that. After the rejection, the stock fell to about $7.60 and the company cut research spending by 60%. Thursday's price is nearly double that low, ahead of a panel that could side with the agency's original concerns.
What to watch
The advisory committee date, and later the FDA's briefing documents, which will show what questions the panel is asked to weigh. The vote itself is the next binary event. The first-quarter 2027 goal date follows.